Utah – Safe Biologics

In the States

Select a state to learn more

State Activity

Utah Governor Herbert Signs Bill Ensuring Patient Access to Interchangeable Biologic MedicinesTransparent communication important for Patients and Physicians

April 02, 2015 03:36 PM Eastern Daylight Time

WASHINGTON–(BUSINESS WIRE)–The Biotechnology Industry Organization (BIO) commends Utah Governor Gary Herbert for signing into law important legislation that serves to update existing Utah laws governing substitution of interchangeable biologic medicines.

The Utah Senate unanimously passed House Bill 279, a bill that amends provisions of the 2013 Pharmacy Practice Act, on March 12th. This action follows House passage of the same bill earlier in March. The bill was signed into law yesterday, April 1st.

Latest News

April 2024 Newsletter

ASBM’s Michael Reilly: Preserve the US Interchangeable Standard that Has Helped Drive Physician and Patient Confidence in Biosimilars In an April interview with EndpointsNews, an FDA official called on Congress to eliminate the distinction between biosimilars (which can be prescribed in place of their reference products by a physician) and “interchangeable” biosimilars, which can be substituted by pharmacists the […]

March 2024 Newsletter

Biden Administration HHS Budget Would Permit Third-Party Substitution of All Biosimilars On March 11th, the Biden Administration released its FY25 HHS Budget. In response, ASBM Executive Director Michael Reilly published a blog post sharing his concerns with the Administration’s proposal to permit widespread automatic (pharmacy-level) substitution of all biosimilars in place of their reference products; without physician approval […]

ASBM’s Michael Reilly: Preserve the US Interchangeable Standard that Has Helped Drive Physician and Patient Confidence in Biosimilars

In an April interview with EndpointsNews, an FDA official called on Congress to eliminate the distinction between biosimilars (which can be prescribed in place of their reference products by a physician) and “interchangeable” biosimilars, which can be substituted by pharmacists the way generics are. Doing so would undermine physician confidence in biosimilars and jeopardize treatment stability for many […]